SCHEMBL2823152

SCHEMBL2823152

CCCCCCCCCC(=O)C(O)C(O)(CO)C(=O)CCCCCCCCC

nearest known ligand 0.50

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
FAAH O00519 7/20 0.46
CES1 P23141 5/20 0.46
CES2 O00748 3/20 0.46
MEN1 O00255 1/20 0.46
CYP1A2 P05177 1/20 0.46
KMT2A Q03164 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8384510 1.00 FAAH (0.46) FAAHCES1CES2MEN1CYP1A2
SCHEMBL8749109 1.00 FAAH (0.46) FAAHCES1CES2MEN1CYP1A2
SCHEMBL8054701 1.00 FAAH (0.46) FAAHCES1CES2MEN1CYP1A2
SCHEMBL8384626 1.00 FAAH (0.46) FAAHCES1CES2MEN1CYP1A2
SCHEMBL4431228 1.00 FAAH (0.46) FAAHCES1CES2MEN1CYP1A2
SCHEMBL10426860 1.00 FAAH (0.46) FAAHCES1CES2MEN1CYP1A2
SCHEMBL8048379 1.00 FAAH (0.46) FAAHCES1CES2MEN1CYP1A2
SCHEMBL8384533 1.00 FAAH (0.46) FAAHCES1CES2MEN1CYP1A2
SCHEMBL8384429 1.00 FAAH (0.46) FAAHCES1CES2MEN1CYP1A2
SCHEMBL8051829 1.00 FAAH (0.46) FAAHCES1CES2MEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10092599-B2 Methods for enhancing hematopoietic stem/progenitor cell engraftment CHILDREN'S MEDICAL CENTER CORPORATION (US) 2018-10-09 US claimed
US-20150246075-A1 METHODS FOR ENHANCING HEMATOPOIETIC STEM/PROGENITOR CELL ENGRAFTMENT CHILDREN'S MEDICAL CENTER CORPORATION 2015-09-03 US claimed
US-20140212949-A1 METHOD FOR PREPARING MICROVESICULAR ADAM15 INDUSTRY ACADEMIC COOPERATION FOUNDATION YONSEI UNIVERSITY (KR) 2014-07-31 US claimed
US-20130203715-A1 USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS PULMATRIX, INC. (US) 2013-08-08 US claimed
WO-2010096264-A2 METHODS FOR ENHANCING HEMATOPOIETIC STEM/PROGENITOR CELL ENGRAFTMENT CHILDREN'S MEDICAL CENTER CORPORATION (US) 2010-08-26 WO claimed
EP-0995430-A2 Use of diacylolycerols for enhancing the barrier function of the skin Beiersdorf Aktiengesellschaft (DE) 2000-04-26 EP claimed
EP-0655907-B1 USE OF DIACYLOLYCEROLS FOR INCREASING THE MELANIN CONTENT IN MELANOCYTES UNIV BOSTON (US) 1999-04-28 EP claimed
US-5700450-A Methods for enhancing melanin synthesis in melanocytes using diacyglycerols and uses thereof THE TRUSTEES OF BOSTON UNIVERSITY (US) 1997-12-23 US claimed
EP-0706369-B1 STIMULATION OF TANNING BY DNA FRAGMENTS UNIV BOSTON (US) 1997-12-17 EP claimed
EP-0706369-A1 STIMULATION OF TANNING BY DNA FRAGMENTS TRUSTEES OF BOSTON UNIVERSITY (US) 1996-04-17 EP claimed
WO-1996009810-A1 METHODS FOR ENHANCING MELANIN SYNTHESIS IN MELANOCYTES USING DIACYLGLYCEROLS AND USES THEREOF TRUSTEES OF BOSTON UNIVERSITY (US) 1996-04-04 WO claimed
WO-1995001773-A9 STIMULATION OF TANNING BY DNA FRAGMENTS 1995-02-16 WO claimed
WO-1995001773-A1 STIMULATION OF TANNING BY DNA FRAGMENTS TRUSTEES OF BOSTON UNIVERSITY (US) 1995-01-19 WO claimed
EP-0334585-A2 Cosmetic composition UNILEVER PLC (GB) 1989-09-27 EP claimed
US-20240156728-A1 MONOVALENT METAL CATION DRY POWDERS FOR INHALATION PULMATRIX OPERATING CO INC (US) 2024-05-16 US disclosed
US-20240150719-A1 MAGNETIC SHEAR BIOREACTOR APPARATUS AND METHODS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2024-05-09 US disclosed
EP-4294919-A1 MAGNETIC SHEAR BIOREACTOR APPARATUS AND METHODS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-12-27 EP disclosed
EP-0334586-A1 Carbohydrate lactam derivatives and their use in cosmetic compositions UNILEVER PLC (GB) 1989-09-27 EP disclosed
US-4855287-A ANTIBIOTICS KOWA COMPANY, LTD. (JP) 1989-08-08 US disclosed
EP-0295092-A2 Skin treatment composition UNILEVER PLC (GB) 1988-12-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203715-A1 USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS TRPV1, TRPC4, TRPC3 FAAH 168/4885CES1 2999/4885CES2 2716/4885
US-20150246075-A1 METHODS FOR ENHANCING HEMATOPOIETIC STEM/PROGENITOR CELL ENGRAFTMENT HCLS1, MCL1, THPO FAAH 3539/4885CES1 2271/4885CES2 1926/4885
US-10092599-B2 Methods for enhancing hematopoietic stem/progenitor cell engraftment HCLS1, MCL1, THPO FAAH 3539/4885CES1 2271/4885CES2 1926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.